Rapport Therapeutics, Inc. Common Stock (RAPP) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 20M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 227K | 265K | 0 | 0 | 0 | 260K | 219K | 208K | 152K | 76K |
| COGS % of Revenue | 1.14% | - | - | - | - | - | - | - | - | - |
| Gross Profit | 19.77M | -265K | 0 | 0 | 0 | -260K | -219K | -208K | -152K | -76K |
| Gross Margin % | 98.87% | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -1.92% | 100% | 100% | 100% | -242.11% | - | - | - | - |
| Operating Expenses | 43.99M | 38.24M | 29.99M | 29.5M | 27.11M | 23.52M | 21.64M | 20.59M | 16.94M | 14.72M |
| OpEx % of Revenue | 219.94% | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 11.5M | 8.25M | 7.71M | 6.82M | 7.54M | 6.32M | 6.1M | 4.9M | 4.44M | 2.92M |
| SG&A % of Revenue | 57.49% | - | - | - | - | - | - | - | - | - |
| Research & Development | 32.72M | 30.26M | 22.28M | 22.68M | 19.57M | 17.2M | 15.54M | 15.69M | 12.5M | 11.8M |
| R&D % of Revenue | 163.58% | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -227K | -265K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -24.21M | -38.51M | -29.99M | -29.5M | -27.11M | -23.52M | -21.64M | -20.8M | -17.09M | -14.79M |
| Operating Margin % | -121.08% | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 10.67% | -63.72% | -38.57% | -41.81% | -58.58% | -58.99% | - | - | - | - |
| EBITDA | -23.99M | -38.24M | -29.73M | -29.24M | -26.86M | -23.26M | -21.42M | -20.59M | -16.94M | -14.74M |
| EBITDA Margin % | -119.94% | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 10.71% | -64.41% | -38.79% | -42.02% | -58.56% | -57.8% | - | - | - | - |
| D&A (Non-Cash Add-back) | 227K | 265K | 256K | 252K | 244K | 260K | 219K | 208K | 152K | 53K |
| EBIT | -24.21M | -38.51M | -26.93M | -29.5M | -27.11M | -23.52M | -21.64M | -20.8M | -17.09M | -13.39M |
| Net Interest Income | 4.36M | 4.75M | 3.06M | 2.76M | 3.04M | 3.54M | 4.1M | 2.68M | 1.81M | 1.38M |
| Interest Income | 4.36M | 4.75M | 3.06M | 2.76M | 3.04M | 3.54M | 4.1M | 2.68M | 1.81M | 1.38M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 4.36M | 4.75M | 3.06M | 2.76M | 3.04M | 3.54M | 4.1M | 2.68M | -5.58M | 1.28M |
| Pretax Income | -19.86M | -33.76M | -26.93M | -26.73M | -24.06M | -19.98M | -17.54M | -18.12M | -22.67M | -13.51M |
| Pretax Margin % | -99.28% | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.04% |
| Net Income | -19.86M | -33.76M | -26.93M | -26.73M | -24.06M | -19.98M | -17.54M | -18.12M | -22.67M | -13.52M |
| Net Margin % | -99.28% | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 17.48% | -68.98% | -53.53% | -47.52% | -6.15% | -47.79% | - | - | - | - |
| Net Income (Continuing) | -19.86M | -33.76M | -26.93M | -26.73M | -24.06M | -19.98M | -17.54M | -18.12M | -22.67M | -13.52M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.42 | -0.72 | -0.71 | -0.75 | -0.68 | -0.57 | -0.50 | -0.50 | -0.12 | -0.07 |
| EPS Growth % | 38.24% | -26.32% | -42% | -50% | -466.67% | -662.03% | - | - | - | - |
| EPS (Basic) | -0.42 | -0.72 | -0.71 | -0.75 | -0.68 | -0.57 | -0.50 | -0.50 | -0.12 | -0.07 |
| Diluted Shares Outstanding | 47.24M | 46.98M | 37.93M | 35.44M | 19.29M | 19.29M | 19.17M | 20.12M | 19.46M | 18.08M |
| Basic Shares Outstanding | 47.24M | 46.98M | 37.93M | 35.44M | 19.29M | 19.29M | 19.17M | 20.12M | 19.46M | 18.08M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |